← IMPACT BIOMEDICAL INC. (IBO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
IMPACT BIOMEDICAL INC. (IBO)
Pharmaceutical Preparations · market cap $55M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-06 (est.)
Earnings
Pipeline
5
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Impact Biomedical Inc. (IBO) is a micro-cap pharmaceutical company with a $49M market cap, 2 employees, and a pipeline anchored by IMP4927 in Phase 3 for ovarian cancer. The company reports $0.0M cash and an estimated 0.1-month runway, making near-term financial survival the dominant question ahead of any clinical milestones.
The catalyst path
- 2026-11-06 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 2 · IMP9064imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Senaparib | Phase 2 | Ovary Cancer |
| IMP4927 | Phase 3 | Ovarian Cancer |
| IMP4297 | Phase 2 | Ovarian Cancer |
| IMP9064 | Phase 2 | Solid Tumor |
| IMP4297(senaparib) | Phase 2 | Advanced Solid Tumours |
Price & technical context
3-month
-12.3%
6-month
-29.1%
12-month
-35.0%
52-wk range
$5.08–$9.87
vs 50-day MA
-9.8%
vs 200-day MA
-18.9%
Realized vol
106.9%
Max drawdown
-92.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IBO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.